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Abstract
Background: We have previously shown that palmitoylation is essential for NRAS leukemogenesis, suggesting that
targeting RAS palmitoylation may be an effective therapy for NRAS-related cancers. For KRAS-driven cancer, although
much research has been focused on the KRAS4B splice variant, which does not undergo palmitoylation, KRAS4A has
recently been shown to play an essential role in the development of carcinogen-induced lung cancer in mice and to
be widely expressed in human cancers. However, the role of palmitoylation in KRAS4A tumorigenesis is not clear.
Methods: The expression of KRAS4A in KRAS-mutated leukemia cell lines and acute myeloid leukemia (AML) cells were
checked using western blotting and reverse transcriptions-quantitative polymerase chain reaction (RT-qPCR) analysis,
respectively. The leukemogenic potentials of oncogenic KRAS4A and its palmitoylation-defective mutants were
examined by a mouse bone marrow transduction and transplantation model and the in vitro transformation assays.
The activation of the RAS downstream signaling pathways and the membrane localizations of the KRAS4A and its
mutants were analyzed via western blot analysis and confocal microscopy, respectively.
Results: We show here that KRAS4A is expressed in human leukemia cell lines and in AML cells harboring KRAS
mutations and that mutation at the palmitoylation site of oncogenic KRAS4A significantly abrogates its leukemogenic
potential. However, unlike NRAS, palmitoylation-defective KRAS4A still induces leukemia in mice, albeit with a much
longer latency. Using NRAS/KRAS4A chimeric constructs, we found that the KIKK motif of KRAS4A contributes to the
transforming activity of KRAS4A. Mutations at both palmitoylation site and the KIKK motif abolish the ability of
oncogenic KRAS4A to induce leukemia in mice.
Conclusions: Our studies suggest that therapies targeting RAS palmitoylation may also be effective in treating KRAS4A
associated malignancies and that interfering the KIKK membrane-targeting motif would enhance the therapeutic
effectiveness.
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Background
RAS small GTPases act as molecular binary switches in sig-
nal transduction regulating cell proliferation, survival, and
differentiation [1]. When bound with GTP, RAS proteins
can mediate diverse cellular processes by engaging many ef-
fector pathways like RAF-MEK-ERK and PI3K-AKT [2, 3].
Mammalian RAS family includes three RAS genes, which
encode four highly homologous proteins: HRAS, NRAS,
KRAS4A, and KRAS4B. The latter two are alternative spli-
cing isoforms differing only at the carboxyl terminus. These
isoforms possess over 90 % identity in the first 166 amino
acid residues (G domain, including switch loops and the
binding surfaces for downstream effectors) and are mainly
diverse in the carboxyl terminal hypervariable region
(HVR). Aberrant activation of the RAS signaling pathway is
common in cancer, including 20–30 % cancers with RAS
mutations [4]. Among RAS genes, KRAS mutations occur
most frequently, accounting for 85 % of RAS mutations,
followed by NRAS (12 %) [4]. HRAS mutation is relatively
rare (3 %) [4].
Despite of intensive research over three decades, can-
cers harboring RAS mutations remain the most difficult
to treat and are refractory to current targeted therapies
[5]. Though strategies to target oncogenic RAS proteins
are emerging, identification of alternative targets that
block RAS signaling is critical to develop therapies for
RAS-driven cancer [6]. The biological activities of RAS
rely on post-translation modifications (PTMs) that target
RAS proteins to cell membranes, particularly the plasma
membrane [7]. One potential approach to block the RAS
oncogenic signaling is, therefore, to inhibit RAS trans-
location to the plasma membrane. RAS are synthesized
as cytosolic proteins. To translocate to membranes, they
need first to be modified by prenylation at the cysteine of
the carboxyl terminal CAAX motif by farnesyltransferases
(FTase) or geranylgeranyltransferase (GGTase), followed by
-AAX proteolysis by RAS converting enzyme (RCE) and
methylation of the exposed, farnesylated cysteine residue by
isoprenylcysteine carboxyl methyltransferase (Icmt) [8].
CAAX motif is the C-terminal tetrapeptide sequence of
RAS proteins (C for cysteine, A for aliphatic amino acid,
and X for serine or methionine). Since prenylation of RAS
by FTase is the obligate step in RAS PTMs, much emphasis
had been placed on developing therapies targeting RAS
farnesylation, but successes are modest to date due to a re-
dundancy of the FTase and GGTase [9]. Inhibitors targeting
both FTase and GGTase in combination have been proved
too toxic to be clinically useful [10, 11].
The prenylation of RAS proteins provides the minimal
signal for their membrane association. NRAS, HRAS, and
KRAS4A are further palmitoylated by palmitoylacyltrans-
ferases (PAT) at the cysteine residue(s) upstream of the
CAAX motif [12–14]. On the other hand, KRAS4B, which
lacks of cysteine residues at its C terminus to accept
palmitoylation modification, traffics directly to the plasma
membrane (PM) by associating its positively charged poly-
lysine residues in HVR with the negatively charged com-
ponent of the inner membrane through electrostatic
interaction [15, 16].
We have previously shown that palmitoylation is es-
sential for NRAS leukemogenesis, suggesting that target-
ing RAS palmitoylation may be an effective therapy for
NRAS-related cancers [17]. For cancers with KRAS mu-
tations, much research has been focused on KRAS4B,
since KRAS4B transcript was shown to be more abun-
dant [18]. However, since most oncogenic mutations
occur in the G domain of RAS, which is identical for
KRAS4A and KRAS4B, KRAS4A should be activated in
cancers harboring KRAS mutations. Although KRAS4A is
dispensable for mouse development [19], accumulating
evidences indicate that the altered KRAS4A/4B ratios may
correlate with progression of lung and colorectal adeno-
carcinoma [20, 21] and that KRAS4A plays an important
role in lung carcinogenesis [22]. Furthermore, a recent
study by improved quantitative RT-PCR revealed that the
KRAS4A splice variant is widely expressed in human can-
cers [23]. Both KRAS isoforms, therefore, should be taken
into account in developing effective cancer therapies.
The role of palmitoylation in KRAS4A tumorigenesis
in vivo is not known. In this study, we compared the ef-
fect of palmitoylation on signaling and leukemogenic
potential of oncogenic NRAS and KRAS4A. We found
that palmitoylation also plays a critical role in KRAS4A
leukemogenesis, but KRAS4A contains an additional
membrane association motif that contributes to the
oncogenic activity of KRAS4A in vivo.
Results
KRAS4A is expressed in human hematologic malignant
cells with KRAS mutations
KRAS mutations have been found in hematologic malig-
nancies [24]. To determine whether KRAS4A is expressed
in blood cancer cells harboring KRAS mutations, we
checked the KRAS4A protein levels with a KRAS4A spe-
cific antibody in acute myeloid leukemia cell lines SHI-1
and NB4, T cell acute lymphoblastic leukemia cell line
CCRF-CEM, as well as diffuse large B cell lymphoma cell
line Toledo. All of these four cell lines derived from hu-
man hematologic malignancies with KRAS mutations. We
observed that KRAS4A is expressed at various levels in
these cell lines, with a particularly high level in SHI-1 and
Toledo cells (Fig. 1a).
To confirm our observation in the hematologic malig-
nant cells from patients, we examined the relative abun-
dance of KRAS4A and KRAS4B mRNA in bone marrow
samples from patients suffering acute myeloid leukemia
(AML) with oncogenic KRAS mutations by reverse
transcriptions-quantitative polymerase chain reaction
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(RT-qPCR) as previously described [23]. We found that
KRAS4A accounts for 6.08–40.21 % of total KRAS tran-
scripts in these samples (Fig. 1b). The results demonstrate
that KRAS4A is expressed in hematologic malignant cells
with KRAS mutations.
Palmitoylation is critical but not essential for the
leukemogenesis by oncogenic KRAS4A
We have previously shown that both oncogenic NRAS
and KRAS4B can induce myeloid leukemia in a mouse
bone marrow transduction/transplantation (BMTT) model
[25, 26]. Here, we checked whether KRAS4A with the
oncogenic mutation G12D (KRAS4AG12D) could also in-
duce leukemia in mice and what is the role of palmitoyla-
tion if KRAS4AG12D does have leukemogenic potential. We
constructed retroviral vectors expressing Myc-tagged KRA-
S4AG12D and its palmitoylation-defective mutant KRA-
S4AG12D/C180S. We infected BM cells isolated from 5-
fluorouracil-treated mice with titer-matched retroviruses
containing KRAS4AG12D or KRAS4AG12D/C180S and then
transplanted these cells into lethally irradiated syngeneic
recipient mice, as previously described [26]. As controls,
Fig. 1 Effects of palmitoylation on leukemogenesis of oncogenic NRAS vs. KRAS4A. a The expression levels of KRAS4A in KRAS-mutated leukemia
cell lines indicated were detected by western blot analysis using an anti-KRAS4A specific antibody. Total RAS and actin were detected as controls.
b Quantification of the relative abundance of KRAS4A and KRAS4B slice variants in bone marrow cells from AML patients with oncogenic KRAS
mutations. The results are presented as means ± SD. c Kaplan-Meier plot of cumulative survival of recipient mice transplanted with bone marrow
cells infected by KRAS4AG12D, KRAS4AG12D/C180S, NRASG12D, or NRASG12D/C181S containing retroviruses. The observation period was over 1 year after
BMT. The median survival is 23, 26, and 86 days for KRAS4AG12D, NRASG12D, and KRAS4AG12D/C180S, respectively. Disease incidences: KRAS4AG12D
(9/10 CMML; 1/10 AML), KRAS4AG12D/C180S (2/10 CMML; 8/10 T-ALL), NRASG12D (5/10 CMML; 5/10 AML). Arrows represent the two moribund
KRAS4AG12D/C180S mice diagnosed as CMML-like disease. P values were determined by the log-rank test. ****P < 0.0001; n = 10 in each group.
d Representative analyses of leukemic bone marrow cells from the moribund KRAS4AG12D/C180S mice with T-ALL like disease (8 out of 10) by
flow cytometry are shown. The MGI vector mice were used as control. e Comparison of CD4+, CD8+ cell percentages in GFP+ BM cells from
the moribund KRAS4AG12D/C180S mice with T-ALL like disease (n = 4) and the MGI vector mice (n = 4). Student t test was used for the statistical
analysis. *P < 0.05. f Representative thymus from moribund KRAS4AG12D/C180S mice with T-ALL like disease and that from the MGI vector mice.
g Comparison of weight of thymus from moribund KRAS4AG12D/C180S mice with T-ALL like disease vs. that from MGI vector mice. The data were
presented as mean ± SEM; *P < 0.05; n = 3 in each group. h Representative analyses of leukemic bone marrow cells from moribund KRAS4AG12D/
C180S mice with CMML-like disease (2 out of 10). The MGI vector mice were used as control
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mice receiving NRASG12D, NRASG12D/C181S, or the MGI
vector-transduced bone marrow cells were generated. We
found that KRAS4AG12D mice succumbed to disease in 20
to 40 days post bone marrow transplantation (BMT), with
similar disease latency as NRASG12D (Fig. 1c). Mice receiv-
ing KRAS4AG12D/C180S-transduced bone marrow cells also
died in succession but with a much longer disease latency
compared with KRAS4AG12D (Fig. 1c). In contrast, all mice
receiving MGI vector or NRASG12D/C181S-transduced bone
marrow cells remained healthy for over one year (Fig. 1c
and data not shown).
We sacrificed the moribund mice receiving KRA-
S4AG12D, KRAS4AG12D/C180S, and NRASG12D-transduced
bone marrow cells to examine their disease phenotype.
Analysis of peripheral blood, bone marrow, livers, and
spleens revealed that KRAS4AG12D mice developed
chronic myelomonocytic leukemia (CMML)- or AML-
like diseases similar to NRASG12D mice as previously
shown [25, 26] (data not shown). All KRAS4AG12D/C180S
mice developed leukocytosis, anemia, and enlarged
spleens and livers, in spite of the normal phenotype in
the first analysis at 3 weeks post BMT (data not shown).
Fluorescence-activated cell sorting (FACS) analyses re-
vealed that 8 out of 10 KRAS4AG12D/C180S mice devel-
oped T cell acute lymphoblastic leukemia (T-ALL) like
disease (Fig. 1d, e). Thymus is enlarged in these mice
(Fig. 1f, g). The rest two KRAS4AG12D/C180S mice devel-
oped a CMML-like disease (Fig. 1h and data not shown).
These results demonstrate that like NRAS, HRAS, and
KRAS4B, oncogenic KRAS4A also possesses leukemogenic
activity, though it induces mostly T-ALL like disease rather
than myeloid leukemia when palmitoylation is blocked. The
difference in cellular localization between different RAS
isoforms may account for the distinguished leukemia phe-
notypes. The data also show that though palmitoylation
plays an important role in KRAS4A leukemogenesis, unlike
NRAS, it is not essential.
Differential roles of palmitoylation on transformation and
signal transduction by oncogenic NRAS and KRAS4A
To further compare the effect of palmitoylation defective-
ness on the oncogenic potential of KRAS4A and NRAS,
we infected the Ba/F3 cell line, an IL-3 dependent mouse
hematopoietic progenitor cell line, with retroviruses con-
taining green fluorescent protein (GFP) alone (MGI vector
control), KRAS4AG12D, KRAS4AG12D/C180S, NRASG12D, or
NRASG12D/C181S, and sorted for GFP-positive cells to gen-
erate corresponding cell lines. After removal of IL-3 from
the culture medium, each group of cells was cultured and
counted every three days in triplicate. Ba/F3 cells stably
expressing GFP alone (MGI vector) stopped growing and
died within first 3 days due to the lack of stimulation by
IL-3, whereas cells expressing NRASG12D and KRA-
S4AG12D continued to proliferation after removal of IL-3
(Fig. 2a). Cells expressing KRAS4AG12D/C180S displayed a
significantly slower proliferation rate compared with
KRAS4A. NRASG12D/C181S, on the other hand, is incapable
of rendering Ba/F3 cells IL-3 independent growth (Fig. 2a).
Overall, the in vitro transforming activities of the onco-
genic NRAS, KRAS4A, and their palmitoylation mutants
correlate with their leukemogenic potentials in vivo.
We previously showed that palmitoylation-deficient
NRASG12D confers morphologic changes, abrogates cell
density-dependent inhibition of growth but does not con-
fer anchorage-independent growth to NIH3T3 cells [17].
To determine the effect of palmitoylation on transform-
ation of NIH3T3 cells by oncogenic KRAS4A, we infected
NIH3T3 cells with KRAS4AG12D and KRAS4AG12D/C180S
retroviruses. NRASG12D, NRASG12D/C181S, KRAS4BG12D,
and the MGI vector were included as controls. To rule
out the possibility whether the myc tag could modify
tumorigenic activity of oncogenic RAS, we also infected
NIH3T3 cells with myc-tagged wild type KRAS4A retro-
virus and found that the myc tag does not alter the bio-
logical activity of wild type KRAS4A in this assay (Fig. 2c).
RAS protein expression levels in NIH3T3 were detected
by western blot analysis (Fig. 2b). It is known that high
levels of RAS can induce cellular senescence [27]. The low
expression level of oncogenic KRAS4B, hence, may be due
to the negative selection of cells with high expression of
KRAS4BG12D.
We found that similar to the morphology of NIH3T3
cells expressing NRASG12D, cells expressing KRAS4AG12D
and KRAS4AG12D/C180S both appeared smaller and more
spindle-shaped than the NRASG12D/C181S and MGI con-
trol cells and began to grow into spheres from the nodules
in a lattice (Fig. 2c), which resemble the cancer stem cells
(CSCs)-like properties ([28] and unpublished data by
Frank McCormick and colleagues). We further assessed
the effect of palmitoylation deficiency on the transforming
potential of KRAS4AG12D by soft agar colony assay.
NIH3T3 cells expressing KRAS4AG12D/C180S generated
fewer colonies than KRAS4AG12D but significantly more
colonies than NRASG12D/C181S (Fig. 2d). These results also
correlate in general with the leukemogenic potentials of
NRAS, KRAS4A, and their palmitoylation mutants in
vivo.
As the in vitro transforming activities of NRAS, KRAS4A,
and their palmitoylation mutants in NIH3T3 cells correlate
well with their transforming activities in Ba/F3 cells as well
as their in vivo leukemogenic potentials, we went on to
check the effect of palmitoylation on NRAS and KRAS4A
signaling using the NIH3T3 cell lines expressing RAS vari-
ants described above. It is well known that the transforming
potential of oncogenic RAS relies on multiple downstream
signaling pathways, including the RAS/RAF/MEK/ERK and
PI3K/AKT pathways [1, 2, 29]. We examined known acti-
vating phosphorylation sites of well-identified signaling
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proteins in the RAS/RAF/MEK/ERK and PI3K/AKT path-
ways in KRAS4AG12D-, KRAS4AG12D/C180S-, NRASG12D-,
or NRASG12D/C181S-expressing NIH3T3 cells by Western
blotting analysis using specific phospho-protein antibodies.
NIH3T3 cells expressing GFP alone or KRAS4BG12D were
included as controls. Cells were serum-starved for 22 h
before lysis to minimize RAS signaling background acti-
vated by serum growth factors.
As expected, the RAF/MEK/ERK pathway is activated
by oncogenic KRAS4B, KRAS4A, and NRAS (Fig. 3a).
Interestingly, palmitoylation deficiency greatly abrogates
the ability of NRASG12D, but not KRAS4AG12D, on activat-
ing c-RAF (Fig. 3a). On the other hand, palmitoylation
deficiency markedly reduces the ability of both NRASG12D
and KRAS4AG12D in activating MEK1/2 and ERK1/2
(Fig. 3a). The results confirm that activation of MEK/ERK
requires conditions other than c-RAF activation [30, 31].
It is also known that c-RAF possesses biological activities
other than that through MEK/ERK activation [32]. The
above results suggest that in addition to inhibition of the
MEK/ERK signaling, completely blocking RAS transform-
ation may involve downstream effectors of c-RAF other
than MEK and ERK.
Also as expected, AKT and S6RP are activated by
oncogenic KRAS4B, KRAS4A, and NRAS (Fig. 3b).
Similar to its effect on c-RAF activation, palmitoylation
deficiency greatly abrogates the ability of NRASG12D, but
not KRAS4AG12D, on activating AKT (Fig. 3b). Palmitoy-
lation deficiency also abrogates the ability of NRASG12D
and, to a lesser extent, of KRAS4AG12D, to activate S6RP
(Fig. 3b).
The results presented here suggest that palmitoyla-
tion deficiency differentially impinges upon signaling
pathways of NRASG12D and KRAS4AG12D, which corre-
lates well with their in vitro and in vivo transforming
activities and that abolishing RAS oncogenic activity
Fig. 2 Effects of palmitoylation on transformation potential of oncogenic NRAS vs. KRAS4A in vitro. a The growth curves of Ba/F3 cells transduced
with the MGI vector control, KRAS4AG12D, KRAS4AG12D/C180S, NRASG12D, or NRASG12D/C181S after removal of IL-3. Student t test was used for the statistical
analysis of the cell numbers in triplicate at each time point. ****P < 0.0001. b Immunoblotting of lysates of NIH3T3 cells stably expressing the GFP
control, KRAS4AG12D, KRAS4AG12D/C180S, NRASG12D, or NRASG12D/C181S using a pan anti-RAS antibody. The top band represents Myc-tagged-RAS; the
bottom band represents endogenous RAS. c Morphology of cultured NIH3T3 cells stably expressing the indicated proteins was observed under light
microscope (original magnification, ×200). d Quantification of anchorage-independent growth of NIH3T3 cells expressing the indicated proteins.
Colonies were counted on day 14 after plating in triplicate. Student t test was used for the statistical analysis. **P < 0.01, ***P < 0.001
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may involve blocking its ability to activate c-RAF, MEK,
ERK, AKT, and S6RP.
The KIKK polybasic motif in HVR of KRAS4A contributes
to the oncogenic activity of KRAS4A
To determine which amino acids contribute to the differ-
ential role of palmitoylation in the oncogenesis of
KRAS4A and NRAS, the HVR sequence of KRAS4AG12D/
C180S and NRASG12D/C181S (Fig. 4a) was swapped to gener-
ate KRAS4A/NRAS chimeric genes named NK and KN
(Fig. 4b). We then ectopically expressed these two
chimeric genes in Ba/F3 and NIH3T3 cell lines. As con-
trols, cells expressing KRAS4AG12D/C180S, NRASG12D/
C181S, or GFP alone were generated. After removal of IL-3,
Ba/F3 cells expressing NK continued to proliferate,
whereas Ba/F3 expressing KN stopped growing and died
soon (Fig. 4c). Similarly, NIH3T3 cells expressing NK
grew into spheres in a lattice as previously described,
whereas NIH3T3 cells expressing KN had a slight morph-
ology change but did not form any sphere (Fig. 4d). Soft
agar colony assay also shows that cells expressing NK gen-
erate significantly greater number of colonies than that of
KN (Fig. 4e). These results indicate that the HVR domain
of KRAS4A render KRAS4AG12D/C180S a higher trans-
forming activity than NRASG12D/C181S.
It was reported that HVR of KRAS4A contains a bipart-
ite polybasic region, designated as PB1 (RLKK, aa167-170)
and PB2 (KIKK, aa182-185), which can independently
deliver KRAS4A to the plasma membrane [23]. Sequence
comparison shows that PB1 is also contained in NRAS
HVR sequence (Fig. 4a). To further clarify which amino
acids in the HVR sequence contribute to the differential
effect of palmitoylation defectiveness on oncogenesis of
KRAS4A and NRAS, we divided HVR of KRAS4A into
three parts: aa166-171, aa172-181, and aa182-189 (part 1,
2, 3 respectively; Fig. 4a, b). We swapped the sequence of
aa172-181 and aa182-189 of KRAS4AG12D/C180S and
NRASG12D/C181S, respectively, and constructed the corre-
sponding retroviral vectors expressing these chimeric RAS
genes named NKN, KNK, NNK, or KKN (Fig. 4b). We
then expressed these genes in Ba/F3 and NIH3T3 cell
lines. We found that Ba/F3 cells expressing KNK or NNK
continue to proliferate after removal of IL-3, whereas Ba/
F3 cells expressing NKN or KKN stop growing and die in
the absence of IL-3 (Fig. 4c). Consistently, NIH3T3 cells
expressing KNK or NNK formed spheres as previously
described, whereas cells expressing KNN or NKN did not
(Fig. 4d). Soft agar colony assay shows that NIH3T3 cells
expressing KNK or NNK generate significant greater
numbers of colonies compared with those expressing
KNN or NKN, indicating that chimeras containing aa182-
189 of KRAS4A possesses higher transforming activity
(Fig. 4e). Interestingly, we found that the colony number
of KKN or NKN expressing cells was significantly more
than KNN or NRASG12D/C181S, suggesting that sequence
aa172-181 contributes to the transforming potential of
KRAS4A as well (Fig. 4e). These results indicate that the
sequence aa182-189 mainly accounts for the differential
role of palmitoylation on the oncogenesis of KRAS4A and
NRAS.
Amino acids between position 182 and 189 consist of
two parts: the KIKK polybasic motif (PB2) and the CAAX
Fig. 3 Effects of palmitoylation on signaling transduction of oncogenic NRAS vs. KRAS4A. Serum-starved lysates of NIH3T3 cells expressing GFP,
KRAS4AG12D, KRAS4AG12D/C180S, NRASG12D, or NRASG12D/C181S were analyzed by western blotting. a Phospho-c-RAF, MEK, and ERK1/2 antibodies
were used to detect the effects of palmitoylation deficiency on the MEK-ERK signaling pathway. b Phospho-AKT and S6RP antibodies were used
to detect the effects of palmitoylation deficiency on the PI3K-AKT signaling pathway. Expression levels of RAS, GFP, and β-Actin were detected as
loading controls
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box, the latter of which is conserved in all RAS proteins
and undergoes prenylation, -AAX proteolysis, and methy-
lation. Hence, the data indicate that the KIKK polybasic
motif in HVR of KRAS4A contributes to the differential
role of palmitoylation in the oncogenesis of KRAS4A and
NRAS.
The role of the KIKK motif on cellular localization of
KRAS4A
To reveal the function of KIKK polybasic motif on
KRAS4A plasma membrane association, we expressed N-
terminal GFP-fusion KRAS4AG12D, KRAS4AG12D/C180S,
KRAS4AG12D/QIQQ (substitution of lysine residuals in
KIKK with glutamines), and KRAS4AG12D/C180S/QIQQ in
NIH3T3 cells and checked the protein membrane
localization by confocal microscope. A clear and intensive
localization of KRAS4AG12D on the plasma membrane of
NIH3T3 was observed, whereas nonpalmitoylated KRA-
S4AG12D/C180S localized mainly on the endomembrane,
with only a small fraction of KRAS4AG12D/C180S proteins
localize on the plasma membrane, particular at some focal
areas (Fig. 5a, b, e). KRAS4AG12D/QIQQ, on the other hand,
mainly localizes on the plasma membrane, with a slight
increase of localization on endomembranes (Fig. 5c, e).
The plasma membrane localization of KRAS4A is com-
pletely abolished by mutating both the palmitoylation site
and KIKK motif (Fig. 5d, e). These results indicate that pal-
mitoylation plays a major role in translocating KRAS4A
proteins from endomembranes to the plasma membrane.
The KIKK polybasic motif only plays a minor role in
translocating KRAS4A from endomembranes to the
plasma membrane; it may help the protein to localize on
special domains of the plasma membrane, allowing
palmitoylation-deficient KRAS4AG12D signals distinctively
from palmitoylation-deficient NRASG12D (Fig. 3).
The plasma membrane-targeting function of KIKK motif
depends on its positively charged residuals
To determine whether the KIKK motif of KRAS4A func-
tions by purely providing electrostatic interaction with
membrane through its basic amino acids or by unknown
interactions, we substituted the lysine residuals in the KIKK
motif of KRAS4AG12D/C180S with one or two uncharged
glutamine residuals (named QIKK, KIQK, KIKQ, QIQK,
QIKQ, and KIQQ, respectively) and overexpressed the mu-
tated genes in NIH3T3 cells. We observed that NIH3T3
Fig. 4 Identification of sequences rendering palmitoylation defective oncogenic KRAS4A transformation active. a The sequence alignment of the
hypervariable regions (HVRs) of NRAS vs. KRAS4A. The shaded areas in green, blue, or orange indicate the sequences separated according to the
lysine enrichment. Part 1: amino acids 166–172; part 2: amino acids 173–182; part 3: amino acids 183–189. b Diagram of NRASG12D/C181S and
KRAS4AG12D/C180S C-terminal domain chimeras. The total C-terminal domain, part 2 or part 3 was swapped respectively to generate NK, KN, NKN,
KNK, NNK, and KKN. c Growth curves of Ba/F3 cells overexpressing the indicated proteins after removal of IL-3. Student t test was used for the
statistical analysis of the cell numbers in each timepoint. ****P < 0.001. d Morphology of cultured NIH3T3 cells stably expressing the indicated
proteins was observed under light microscope (original magnification, ×200). e Quantification of anchorage-independent growth of NIH3T3 cells
expressing the indicated proteins. Colonies were counted on day 14 after plating in triplicate. Student t test was used for the statistical analysis.
*P < 0.05, **P < 0.01, ***P < 0.001
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cells expressing QIKK, KIQK, or KIKQ formed spheres in a
lattice and had other morphology close to KRAS4AG12D/
C180S, whereas cells expressing QIQK, QIKQ, or KIQQ had
spindle-shaped morphology but did not form any sphere
(Fig. 6a). Soft agar colony assay also showed a gradual
decline in the colony numbers with the decrease of lysine
residual numbers in the KIKK motif (Fig. 6b). Meanwhile,
no obvious changes in the sphere morphology and the
transforming potential were observed after substitution of
the lysine residuals in the KIKK motif with arginine resid-
uals (named KRAS4AG12D/RIRR and KRAS4AG12D/C180S/
RIRR, Fig. 6c, d). These results indicate that the KIKK motif
functions by providing electrostatic interaction with the
plasma membrane through its positively charged amino
acids.
To check the effect of KIKK mutations on signaling of
KRAS4A, we infected NIH3T3 cells with retroviral con-
structs expressing KRAS4AG12D, KRAS4AG12D/C180S, KRA-
S4AG12D/QIQQ, or KRAS4AG12D/C180S/QIQQ. Cells were
starved for 22 h and then lysed for detection of the activa-
tion of signaling proteins c-RAF, MEK1/2, ERK1/2, AKT,
and S6RP. We observed that in KRAS4AG12D/QIQQ express-
ing cells, the phosphorylation levels of MEK1/2, ERK1/2,
AKT, and S6RP were lower than KRAS4AG12D but a
slightly higher than KRAS4AG12D/C180S (Fig. 6e). No obvi-
ous change in the phosphorylation level of c-RAF Ser338 in
KRAS4AG12D/QIQQ cells was observed compared with that
of KRAS4AG12D and KRAS4AG12D/C180S. Interestingly, the
ability of KRAS4AG12D to active c-RAF, MEK1/2, ERK1/2,
AKT, and S6RP is abolished by mutating both the
palmitoylation site and the KIKK motif (KRAS4AG12D/
C180S/QIQQ). In contrast, substitution of the lysine residuals
with arginine residuals in the KIKK motif does not signifi-
cantly affect KRAS4AG12D signaling activity. These results
further support the conclusion that the KIKK polybasic
motif in HVR of KRAS4A contributes to the differential
role of palmitoylation in the oncogenic signaling of
KRAS4A and NRAS.
The relative importance of palmitoylation and the KIKK
motif on leukemogenic potential of KRAS4A
To further examine the role of KIKK motif in KRAS4A
leukemogenesis, we used the BMTT model with retrovi-
ruses containing KRAS4AG12D/QIQQ or KRAS4AG12D/
C180S/QIQQ. Mice receiving KRAS4AG12D, KRAS4AG12D/
C180S, or MGI vector-transduced bone marrow cells were
used as controls. As previously shown, KRAS4AG12D rap-
idly and efficiently induces a CMML- or AML-like disease
in mice. Under the same experimental conditions, the dis-
ease latency of KRAS4AG12D/QIQQ was only slightly pro-
longed compared to KRAS4AG12D, while KRAS4AG12D/
C180S mice survived a much longer time (Fig. 7a). In con-
trast, all KRAS4AG12D/C180S/QIQQ mice remained healthy
during the course of experiment (Fig. 7a). Immunopheno-
type analysis showed that mice transfected KRAS4AG12D/
QIQQ also developed CMML- or AML-like disease
(Fig. 7b), while the majority of KRAS4AG12D/C180S mice
developed T-ALL like disease as previously described
(Fig. 1d and data not shown). All groups of mice in mori-
bund or over 1 year were sacrificed for pathological
Fig. 5 KIKK of KRAS4A functions as a second plasma membrane association motif. NIH3T3 cells expressing GFP-fused KRAS4AG12D a, KRAS4AG12D/C180S
b, KRAS4AG12D/QIQQ c, or KRAS4AG12D/C180S/QIQQ d were visualized on a Leica TCS 7300 Spectral Confocal Microscope (original magnification, ×630). e
The comparison of plasma membrane localization ratios of each KRAS4A mutant. Ten representative cells of each group were photographed and
analyzed by LAS AF Lite Software. PM plasma membrane; Student t test was used for the statistical analysis. ****P < 0.0001
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analysis. The spleens of KRAS4AG12D/C180S/QIQQ mice are
normal compared with KRAS4AG12D, KRAS4AG12D/QIQQ,
or KRAS4AG12D/C180S (Fig. 7c). These results indicate that
palmitoylation plays a more important role than the KIKK
plasma membrane-targeting motif in KRAS4AG12D
leukemogenesis, yet blocking both could completely abol-
ish the ability of oncogenic KRAS4A to induce leukemia.
Discussion
Accumulating evidence has indicated that the KRAS4A
splice variant plays an important role in tumorigenesis
[20–23]. Understanding the oncogenic potential of
KRAS4A in vivo and the ways to block its oncogenic
signaling is important for developing effective cancer
therapies. Here, we show that KRAS4A has a similar
Fig. 6 KIKK motif of KRAS4A functions by providing a positive charged region. a Morphology of cultured NIH3T3 cells stably expressing
KRAS4AG12D/C180S with KIKK motif mutated to QIKK, KIQK, KIKQ or QIQK, QIKQ, KIQQ was observed under light microscope (original magnification,
×200). b, d Quantification of anchorage-independent growth of NIH3T3 cells expressing the indicated proteins. Colonies were counted on day 14
after plating in triplicate. Student t test was used for the statistical analysis. ****P < 0.0001. c Morphology of cultured NIH3T3 cells stably expressing
KRAS4AG12D, KRAS4AG12D/C180S, KRAS4AG12D/QIQQ, or KRAS4AG12D/C180S/QIQQ was observed under light microscope (original magnification, ×200).
e Serum-starved lysates of NIH3T3 cells expressing the indicated proteins were analyzed by western blotting to detect the phosphorylation levels
of c-RAF, MEK, ERK1/2, AKT, and S6RP. Expressions of RAS, GFP, and β-actin were used as loading controls
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leukemogenic potential as NRAS (Fig. 1), as well as
KRAS4B (data not shown), when expressed under the
same promoter. Palmitoylation is very important for
KRAS4A leukemogenesis, but it is not essential as that
in case of NRAS. The KIKK motif in KRAS4A func-
tions as an alternative membrane-targeting motif and
makes a contribution to leukemogenesis by oncogenic
KRAS4A.
Consistent with the results in our previous work,
NRASG12D palmitoylation mutant completely loses the cap-
acity to activate MEK-ERK and PI3K-AKT pathways in
NIH3T3 cells [17]. Unlike NRASG12D, although defective in
activating MEK, ERK, and S6RP, the KRAS4AG12D palmi-
toylation mutant retains most of its ability to activate c-
RAF and AKT, coincident with the sphere morphology and
the more colony numbers of KRAS4AG12D/C180S-expressing
Fig. 7 Contributions of palmitoylation and KIKK motif on leukemogenic potential of oncogenic KRAS4A. a Kaplan-Meier plot of cumulative survival of
recipient mice transplanted with bone marrow cells infected by KRAS4AG12D (n= 5), KRAS4AG12D/C180S (n= 5), KRAS4AG12D/QIQQ (n= 11), KRAS4AG12D/C180S/
QIQQ (n= 10) containing retroviruses. The MGI vector mice (n= 5) were observed as control. P values were determined by the log-rank test. **P< 0.01,
****P< 0.0001. b Immunophenotyping of the leukemic bone marrow cells isolated from the KRAS4AG12D, KRAS4AG12D/QIQQ, and KRAS4AG12D/C180S/QIQQ
moribund mice by flow cytometry. The myeloid lineage markers include Gr-1 and Mac-1. All the cells are GFP positive gated. c Spleens from the mice of
each group were shown as indicated. d Comparison of the spleen weights of each group mice. The data were presented as mean ± SEM. Student t test
was used for the statistical analysis. **P< 0.01, ***P< 0.001; n= 3 in each group
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NIH3T3 cells compared with NRASG12D/C181S-expressing
cells. These data suggest that though the plasma membrane
localization of KRAS4AG12D is greatly reduced by the pal-
mitoylation mutation (Fig. 5), the KIKK motif may target
KRAS4A to a special domain in the plasma membrane,
allowing it to activate c-RAF and AKT. These results indi-
cates that the KIKK motif, assisting in the KRAS4A plasma
membrane translocation, may mainly contribute to the
differential effect of palmitoylation in the leukemogenesis
of oncogenic KRAS4A and NRAS. These results also sug-
gest that palmitoylation would be an effective target for
both oncogenic KRAS4A and NRAS associated cancer
therapy and that the KIKK motif should also be taken into
account in the case of oncogenic KRAS4A associated
cancer.
The KIKK motif has been recognized as a membrane-
targeting motif [12, 23], but the mechanism was unknown.
Electrostatical interaction of polybasic motifs with nega-
tively charged lipids promotes protein binding with plasma
membrane [33, 34]. But, the polybasic region of KRAS4B
consists of a stretch of six lysine residuals. To test whether
the KIKK motif target KRAS4A to membrane through elec-
trostatical interaction or specific protein-protein inter-
action, we substituted all lysine residuals in the KIKK motif
with arginine residuals and found no obvious functional
change of oncogenic KRAS4A. In addition, substitution of
lysine residuals in the KIKK motif with one, two, or three
glutamine residuals results in its gradual decrease of trans-
forming potential, suggesting that the KIKK motif of
KRAS4A functions by providing electrostatic interaction
with the plasma membrane through its positively charged
amino acids.
Sequence analysis shows that both KRAS4A and NRAS
harbor an RxKK (x: methionine or leucine) motif, which is
designated as PB1 (polybasic domain 1) and was shown to
promote the membrane localization [12, 23]. Our data
show that mutating both the palmitoylation site and the
KIKK motif like the effect of mutating the palmitoylation
site in NRASG12D, completely abolishes KRAS4AG12D’s
leukemogenic potential. These data suggest that the RxKK
motif is a much weaker membrane-targeting motif com-
paring to palmitoylation and KIKK. In addition to the
KIKK motif and the RxKK motif, amino acids between
172 and 181 from KRAS4A increases the transforming ac-
tivity of NRASG12D in NIH3T3, but not Ba/F3, cells
(Fig. 4c, e), indicating that this region in KRAS4A may
also help its plasma membrane localization.
The fraction of KRAS4AG12D, even the QIQQ mutant
KRAS4AG12D, localized on the plasma membrane is signifi-
cantly more than that of NRASG12D (Fig. 5 and data not
shown). It is possible that palmitoylation of KRAS4A is
more efficient than that of NRAS. It is noticeable that the
amino acid sequence around the palmitoylation site is dif-
ferent between NRAS and KRAS4A, raising the possibility
that palmitoylation of NRAS and KRAS4A may be cata-
lyzed by different palmitoylacyltransferases. Given its im-
plication in developing targeted cancer therapies, this
possibility should be tested in the future.
Recurrent mutations of slicing factor genes have been
found in hematological malignances, as well as some solid
tumors, indicating aberrant splicing is involved in the
pathogenesis of cancer [35–38]. Our data show that
KRAS4A is expressed in all hematological malignant cell
lines tested and that some cell lines harbor a particularly
high level of KRAS4A (Fig. 1a). It is possible that deregu-
lated splicing facilitates the expression of the KRAS4A
splice variant in certain hematological malignant cells. Un-
derstanding the mechanism by which the KRAS4A/4B
splicing is regulated might help to reveal alternative strat-
egies for cancer therapy.
Conclusions
Palmitoylation palys a critical role in KRAS4A
leukemogenesis, but it is not essential as that in case of
NRAS. The KIKK motif in KRAS4A functions as an add-
itional membrane-targeting motif and makes a contribution
to leukemogenesis by oncogenic KRAS4A. The studies
suggest that therapies targeting KRAS4A palmitoylation
might be effective in treating related malignancies and that
interfering the KIKK membrane-targeting motif would en-
hance the therapeutic effectiveness.
Methods
DNA constructs
NRASG12D- and NRASG12D/C181S-containing MSCV-GFP-
IRES (MGI) retroviral constructs were generated as previ-
ously described [17]. Wild-type KRAS4A human cDNA
(NCBI accession number: NM_033360.3) was cloned into
the MGI vector with N-terminal Myc-tag. KRAS4AG12D
(replacing the glycine residual at codon 12 with aspartic




S4AG12D/C180S/QIKQ, and KRAS4AG12D/C180S/KIQQ mutants
were generated using Quickchange Site-Directed Muta-
genesis Kit (Stratagene, #200518). Genes containing
fragment-swapped mutants NK, KN, NKN, KNK, NNK,
and KKN were synthesized by GENEWIZ, followed by
subcloning them into the MGI vector. Retroviral vectors
expressing KRAS4AG12D, KRAS4AG12D/C180S, KRA-
S4AG12D/QIQQ, and KRAS4AG12D/C180S/QIQQ mutants as
N-terminal GFP-fusion proteins were created by cloning
these mutational genes into EGFP-C1 plasmids, followed
by subcloning them into the MSCV-IRES (without GFP)
vector to generate MSCV-GFP/RAS mutants-IRES plas-
mids. Genes containing fragment-switching mutants NK,
KN, NKN, KNK, NNK, and KKN were synthesized by
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GENEWIZ, followed by subcloning them into the MGI
vector. All constructs were confirmed by DNA sequencing
before use.
RT-qPCR
Bone marrow total RNA of three AML patient samples
with oncogenic KRAS mutations were collected from
the centers of Shanghai Institute of Hematology (SIH).
The primers for KRAS4A and KRAS4B were designed as
previously described [23]. Primer sequences are as fol-
lows: for KRAS4A, forward: 5′-agacacaaaacaggctcagga-
3′, reverse: 5′-ttcacacagccaggagtcttt-3′; for KRAS4B,
forward: 5′-gactggggagggctttcttt- 3′, reverse: 5′-gcatcat-
caacaccctgtct-3′. Results were normalized to a standard
curve built by a dilution of MGI-KRAS4A and MGI-
KRAS4B plasmid DNA.
The study was approved by the ethics committees of all
participating centers. All patients were given informed con-
sent for cryopreservation of bone marrow (BM) according
to the Declaration of Helsinki.
Retrovirus production and tittering
Retroviruses were produced with the constructs de-
scribed above by individually cotransfecting them with
the Pcl-Eco retrovirus packaging vector into the Bosc23
retroviral packaging cell line using a calcium phosphate
precipitation method as previously described [25, 26].
Retroviral supernatant was harvested 48 h after transfec-
tion and tittered as previously described [25, 26].
Bone marrow transduction/transplantation
Retroviral transduction and BM transplantation experi-
ments were performed as previously described [26]. Briefly,
BM cells were isolated from the 6–8-week-old donor mice
pretreated with 5-fluorouracil (250 mg/kg). BM cells were
infected with retroviruses each day for 2 days in transplant
medium, followed by injecting 4 × 105 cells into the tail vein
of each lethally irradiated (2 × 3.8 Gy, 4 h between each
dose) female recipient BALB/c mice. Retroviral titers were
matched to 2 × 106 TFUs before BM infection. Recipient
mice were monitored weekly for signs of disease beginning
on day 14 after transplantation. All the animal experiments
were approved by The Animal Care and Welfare Commit-
tee of Shanghai Jiao Tong University School of Medicine.
Hematological and immunophenotypic analysis
Peripheral blood (PB) was obtained from mice by tail
bleeding and analyzed by using a pocH-100iV Diff
hematology analyzer (Sysmex Corporation). After lysing
the RBC, PB, bone marrow, spleen, or thymus cells were
stained with conjugated antibodies to specific surface an-
tigens. Mac-1, Gr-1, CD19, B220, CD3, CD4, and CD8
were used separately or in combination for immunophe-
notypic analysis of hematopoietic or leukemic cells (BD
Pharmingen). All flow cytometric analyses were per-
formed on an LSR II system (BD Biosciences). Data were
analyzed with FlowJo software (Tree Star Inc.).
Cell culture
Bosc23 cells were grown in Dulbecco’s Modified Eagle’s
Medium (DMEM), 10 % Fetal bovine serum (GIBCO,
Catalog 10099-141), and 1× penicillin/streptomycin.
NIH3T3 cells were cultured in DMEM, 10 % bovine
serum (GIBCO, catalog #16170078), and 1× penicillin/
streptomycin. Ba/F3 cells were maintained in 1640
medium supplemented with 10 % fetal bovine serum
(FBS), 1× penicillin/streptomycin, and 10 % IL-3 con-
taining WEHI-3B conditional medium. NIH3T3 and Ba/
F3 cell lines stably expressing KRAS4AG12D and mutant
KRAS4AG12D genes were generated by retroviral trans-
duction as described [17, 26]. All cell lines were sorted
by FACS to >95 % GFP positive homogeneity.
Cell proliferation assay and microscopic analysis
After sorting by FACS, Ba/F3 cells transduced with
KRAS4AG12D or mutant KRAS4AG12D genes expressing
retroviruses were washed with 1640 twice to remove IL-
3 and resuspended with 1640 containing 10 % FBS and
1× penicillin/streptomycin. Cells were plated in triplicate
into 6-cm dishes in the absence of IL-3 and were stained
with trypan blue to exclude nonviable cells and counted
manually under a light microscope every 3 days until the
cell lines fully grew or died. Student t test was used for
the comparison of the cell numbers in each time point.
NIH3T3 cells expressing KRAS4AG12D or mutant KRA-
S4AG12D genes formed tight spheres after culturing for
6 days and were photographed using an Olympus digital
camera.
Soft agar colony forming assay
To generate 0.6 % soft agar, 1.5 ml 4 % agarose with 8.5-ml
cell culture media (Dulbecco’s modified Eagle’s medium +
20 % bovine serum+ 1.2 times Pen-Strep) was mixed. A
total of 2 mL of 0.6 % bottom agar (incubated in 42 °C) was
then platted into each well of a 6-well tissue culture plate.
FACS-purified NIH3T3 cell lines expressing MGI vector or
RAS mutants were diluted to 2 × 105 cells/ml, 2 × 104 cells/
ml, or 2 × 103 cells/ml in. Triplicate 3-mL cells suspended
in 0.3 % soft agar (cell dilution + 0.6 % soft agar with 1:1
ratio) were added on top of the jellified bottom agar for
each type of transduced cells and incubated in CO2 incuba-
tor at 37 °C. Colonies were counted under a light micro-
scope at day 14 after plating.
Western blot analysis
Western blot analyses were performed as previously de-
scribed [17, 26, 39]. Briefly, 90 % confluent NIH3T3 cells
were serum-starved for 22 h. Cells were counted and
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lysed in 1× SDS running buffer, heated at 100 °C for
10 min, and centrifuged to remove debris. Lysates were
resolved on 10 % polyacrylamide gels, transferred to
nitrocellulose membranes, and blotted with the follow-
ing primary antibodies: anti-KRAS4A specific antibody
(1:500; Santa Cruz Biotechnology, sc-522), anti-RAS
antibody (1:2000; Cell Signaling Technology, #3965), anti-
actin (1:5000; Sigma-Aldrich, A1978), anti-GFP (1:2000;
Cell Signaling Technology, #2555), and phospho-c-RAF,
c-RAF, phoshpo-MEK1/2, MEK1/2, phospho-ERK1/2,
ERK1/2, phospho-AKT, AKT, phospho-S6RP, and S6RP
(All 1:2000; Cell Signaling Technology). HRP-labeled goat
anti-mouse IgG or goat anti-rabbit IgG was used as a sec-
ondary antibody.
Cellular localization analysis of RAS proteins
NIH3T3 cells expressing KRAS4AG12D with GFP fused
to its N terminus or expressing GFP-fusion versions of
KRAS4AG12D PTM or KIKK motif mutant proteins were
grown overnight. Fluorescence was visualized and photo-
graphed on a Leica TCS 7300 Spectral Confocal Micro-
scope. The images were analyzed by using LAS AF Lite
Software (Leica). The plasma membrane localization ratios
of KRAS4A mutants were counted by (pixel(plasma mem-
brane)/pixel(sum)). Ten representative cells of each group
were counted and analyzed. Student t test was used for
statistical data analysis.
Statistical analysis
Graphpad Prism 6 software was used for statistical data
analysis. Student t test was used for mean comparison,
whereas the Kaplan-Meier survival curve and log-rank
test were used for survival analysis.
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